Evidence map›Paper›PMID 28126151›Full record

ArticleMayo Clinic proceedings2016

5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia.

Lauren P Wallner, Julia R DiBello, Bonnie H Li, Stephen K Van Den Eeden, Sheila Weinmann, Debra P Ritzwoller, Jill E Abell, Ralph D'Agostino, Ronald K Loo, David S Aaronson and 3 more

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Mayo Clinic proceedings, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Lauren P WallnerDepartment of Medicine, University of Michigan, Ann Arbor, MI; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA. Electronic address: lwallner@med.umich.edu.
Julia R DiBelloWorldwide Epidemiology, GlaxoSmithKline, Collegeville, PA.
Bonnie H LiDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA.
Stephen K Van Den EedenDivision of Research, Kaiser Permanente Northern California, Oakland, CA.
Sheila WeinmannCenter for Health Research, Kaiser Permanente Northwest, Portland, ORG.
Debra P RitzwollerInstitute for Health Research, Kaiser Permanente Colorado, Denver, CO.
Jill E AbellReal World Evidence, Janssen, Philadelphia, PA.
Ralph D'AgostinoDepartment of Biostatistical Science, Wake Forest University, Winston-Salem, NC.
Ronald K LooDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA.
David S AaronsonDivision of Research, Kaiser Permanente Northern California, Oakland, CA.
Kathryn Richert-BoeCenter for Health Research, Kaiser Permanente Northwest, Portland, ORG.
Ralph I HorwitzTemple University, Philadelphia, PA; Institute of Medicine, Washington, DC.
Steven J JacobsenDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA.
Kaiser Permanente · USKaiser Permanente Center for Health Research · USGlaxoSmithKline (United States) · USJanssen (United States) · USNational Academy of Medicine · USWake Forest University · US

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
NCI NIH HHS P30 CA012197
6 · The paper itself

Abstract

objectiveTo compare the risk of prostate cancer mortality among men treated with 5- alpha reductase inhibitors (5-ARIs) with those treated with alpha-adrenergic blockers (ABs) in community practice settings. PATIENTS AND

methodsA retrospective matched cohort (N=174,895) and nested case-control study (N=18,311) were conducted in 4 regions of an integrated health care system. Men 50 years and older who initiated pharmaceutical treatment for benign prostatic hyperplasia between January 1, 1992, and December 31, 2007, and had at least 3 consecutive prescriptions were followed through December 31, 2010. Adjusted subdistribution hazard ratios, accounting for competing risks of death, and matched odds ratios were used to estimate prostate cancer mortality associated with 5-ARI use (with or without concomitant ABs) as compared with AB use.

resultsIn the cohort study, 1,053 men died of prostate cancer (mean follow-up, 3 years), 15% among 5-ARI users (N= 25,388) and 85% among AB users (N=149,507) (unadjusted mortality rate ratio, 0.80). After accounting for competing risks, it was found that 5-ARI use was not associated with prostate cancer mortality when compared with AB use (adjusted subdistribution hazard ratio, 0.85; 95% CI, 0.72-1.01). Similar results were observed in the case-control study (adjusted matched odds ratio, 0.95; 95% CI, 0.78-1.17).

conclusionAmong men being pharmaceutically treated for benign prostatic hyperplasia, 5-ARI use was not associated with an increased risk of prostate cancer-specific mortality when compared with AB use. The increased prevalence of high-grade lesions at the time of diagnosis noted in our study and the chemoprevention trials may not result in increased prostate cancer mortality.

Indexed as

5-alpha Reductase InhibitorsAdrenergic alpha-AntagonistsAgedCohort StudiesHumansMaleMiddle AgedOdds RatioProstatic HyperplasiaProstatic NeoplasmsRetrospective StudiesRisk AssessmentRisk FactorsTreatment Outcome5-alpha Reductase InhibitorsAdrenergic alpha-Antagonists

Identifiers

PMID28126151
PMCPMC8080281
OpenAlexW2540045475

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.